We are studying whether Felzartamab can help patients experiencing late antibody-mediated rejection after a transplant. This research aims to improve treatment options for these patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Late antibody mediated renal transplant rejection is a condition that occurs when the immune system produces antibodies against the transplanted kidney, leading to damage and dysfunction of the organ over time.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.